Personalised Cancer Medicine Flashcards 2025

Indications determined by the organ of origin
Prostate Cancer
Prostate Cancer

Standard

Recommended

Currently not recommended
  • BRCA1 and BRCA2*
  • Microsatellite instability*
  • HRR Profound panel* (somatic)
  • Androgen receptor aberrations
  • PDL1
  • PTEN
* by either IHQ (MLH1, PMS2, MSH2 a MSH6) or by genomic study (BAT25 y BAT26, D2S123, D5S346 and D17S250).
Download table
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.

References:

1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440.

2. To SQ, Kwan EM, Fettke HC, et al. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 Jun;73(6):818-821. doi: 10.1016/j.eururo.2018.01.007.

3. González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clin Transl Oncol. 2021 May;23(5):969-979. doi: 10.1007/s12094-021-02561-5.

4. Fenton SE, VanderWeeler DJ, Rebbeck TR, Chen DL. Advancing Prostate Cancer Care: Treatment Approaches to Precision Medicine, Biomarker Innovations, and Equitable Access. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433138. doi: 10.1200/EDBK_433138.